US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Monkeypox Concept

1,888.73

+7.810.42%

Number of Gainers:7

Number of Losers:3

Number of Flat:1

PE:- -

High:1,919.28

Open:1,904.45

Low:1,875.64

Close:1,880.93

Volume:10.07M

Turnover:611.38M

Market Cap:208.87B

Float Cap:208.36B

Loading ...

Gilead Sciences Nears Acquisition of Ouro Medicines for Up to $2 Billion, Financial Times Says

MT Newswires Live

BRIEF-Gilead Nears Up To $2 Billion Deal For Autoimmune Biotech Ouro Medicines - FT

Gilead Nears up to $2Bn Deal for Autoimmune Biotech Ouro Medicines - FT

THOMSON REUTERS

Gilead Will Pay Privately Held Ouro’s Investors Roughly $1.5Bn Upfront in Cash and at Least Extra $500Mn IF Certain Clinical Trial Milestones Are Hit - FT

THOMSON REUTERS

Talks Between Gilead and Ouro Medicines Are at an Advanced Stage and a Deal Could Be Announced in the Coming Days - FT

THOMSON REUTERS

Barclays Adjusts Viatris Price Target to $17 From $15, Maintains Overweight Rating

MT Newswires Live

Shareholders Sue Inovio Pharmaceuticals Over DNA Technology Claims

Xilio Therapeutics Q4 license revenue rose 100% to USD 14 million, net income was USD 10 million

Japan MHLW approves Viatris Effexor SR for adult generalized anxiety disorder

Viatris Advances Innovative Portfolio With Approval of Effexor® in Japan for Adults With Generalized Anxiety Disorder (Gad)

THOMSON REUTERS

Assessing Viatris (VTRS) Valuation As Investor Event Outlines Long Term Plans Through 2030

Simply Wall St.

How Investors May Respond To Quest Diagnostics (DGX) Expanding Blood-Based Cancer Screening And Boardroom Expertise

Simply Wall St.

Inovio Pharmaceuticals Inc. Stock Underperforms Friday When Compared To Competitors

Tonix Pharmaceuticals Holding Corp. Announces Annual Shareholder Meeting

Emergent BioSolutions Inc. Announces Annual Meeting of Stockholders

Gilead Sciences Inc. Stock Underperforms Friday When Compared To Competitors

E-Home Household Service set for Nasdaq delisting hearing on April 16, 2026

Gilead Sciences Inc. Announces Annual Stockholders Meeting

Gilead Ends Obeldesivir Filovirus Prophylaxis Trial: What It Means for GILD Investors

Virax Biolabs Group Ltd. COO and Director Nigel William McCracken files initial beneficial ownership statement

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK4583/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4583","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4583\",,,,,undefined,":{"symbol":"BK4583","market":"US","secType":"PLATE","nameCN":"Monkeypox Concept","latestPrice":1888.747,"timestamp":1774291373832,"preClose":1880.932,"halted":0,"volume":10069670,"delay":0,"changeRate":0.004155,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":7.814941,"latestTime":"03-23 14:42:54 EDT","open":1904.4513,"high":1919.2766,"low":1875.6362,"amount":611379077.121186,"amplitude":0.023201,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1774296000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":4.675681,"peRate":36.68023,"turnoverRate":0.003754,"increases":7,"decrements":3,"flats":0,"marketCap":208872335951,"floatMarketCap":208364550516.25},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4583\",,,,,undefined,":{"symbol":"BK4583","high":1919.2766,"amplitude":0.023201,"preClose":1880.932,"low":1875.6362,"pbRate":"4.675681","latestPrice":1888.727,"volume":10069055,"delay":0,"open":1904.4513,"prevYearClose":1682.3505,"prevWeekClose":1880.932,"prevMonthClose":2038.3699,"prevQuarterClose":1682.3505,"fiveDayClose":1977.8417,"twentyDayClose":2055.7751,"sixtyDayClose":1707.4207,"secType":"PLATE","market":"US","turnoverRate":0.003754,"peRate":36.68023,"marketCap":208853723727,"floatMarketCap":208345987444.25,"timestamp":1774291370448,"nameCN":"Monkeypox Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4583\",,,,undefined,":{"bkCode":"BK4583","up":7,"down":3,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4583\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2621088370","title":"Gilead Sciences Nears Acquisition of Ouro Medicines for Up to $2 Billion, Financial Times Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2621088370","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621088370?lang=en_us&edition=fundamental","pubTime":"2026-03-24 00:46","pubTimestamp":1774284389,"startTime":"0","endTime":"0","summary":"Gilead Sciences Nears Acquisition of Ouro Medicines for Up to $2 Billion, Financial Times Says","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0965509283.SGD","LU1023059063.AUD","LU0889565916.HKD","LU1778281490.HKD","BK4583","SG9999015945.SGD","SG9999015952.SGD","IE0002270589.USD","LU0965508806.USD","IE00BZ1G4Q59.USD","LU2324357040.USD","LU1037948541.HKD","LU2112291526.USD","LU0320765992.SGD","BK4588","LU0114720955.EUR","IE00B3T34201.USD","IE00BSNM7G36.USD","LU1934455277.USD","LU1066053197.SGD","LU1674673691.USD","BK4568","LU1061106388.HKD","IE00B7SZLL34.SGD","GILD","IE00BKVL7J92.USD","LU0234570918.USD","IE00B19Z3B42.SGD","BK4532","BK4550","BK4139","LU0882574055.USD","MDCO","LU2089984988.USD","LU0109394709.USD","LU1674673428.USD","IE00B19Z3581.USD","LU1839511570.USD","LU1066051498.USD","LU0289739699.SGD","BK4585","LU0965509010.AUD","LU1037948897.HKD","LU1934455194.USD","LU1571399168.USD","LU1430594728.SGD","LU2468319806.SGD","SG9999015986.USD","LU0058720904.USD","BK4578"],"gpt_icon":0},{"id":"2621045700","title":"BRIEF-Gilead Nears Up To $2 Billion Deal For Autoimmune Biotech Ouro Medicines - FT","url":"https://stock-news.laohu8.com/highlight/detail?id=2621045700","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621045700?lang=en_us&edition=fundamental","pubTime":"2026-03-24 00:37","pubTimestamp":1774283834,"startTime":"0","endTime":"0","summary":"BRIEF-Gilead Nears Up To $2 Billion Deal For Autoimmune Biotech Ouro Medicines - FTMarch 23 (Reuters) - GILEAD NEARS UP TO $2BN DEAL FOR AUTOIMMUNE BIOTECH OURO MEDICINES - FTGILEAD WILL PAY PRIVATELY","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nFWN40B108:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4578","IE0002270589.USD","SG9999015986.USD","BK4588","BK4566","LU0889565916.HKD","LU1023059063.AUD","LU1066053197.SGD","LU1839511570.USD","BK4568","LU0823416689.USD","LU1571399168.USD","BK4583","LU0289739699.SGD","LU2087621335.USD","IE00B19Z3581.USD","LU2324357040.USD","LU1430594728.SGD","LU0965509283.SGD","LU1674673428.USD","LU1057294990.SGD","BK4585","LU2468319806.SGD","LU1061106388.HKD","LU1674673691.USD","LU0965509010.AUD","LU0965508806.USD","LU1778281490.HKD","SG9999015978.USD","BK4532","IE00BKVL7J92.USD","LU2112291526.USD","LU2089984988.USD","GILD","SG9999015952.SGD","LU0234570918.USD","LU1934455277.USD","LU1066051498.USD","IE00BZ1G4Q59.USD","LU1037948541.HKD","IE00B3T34201.USD","LU0861579265.USD","IE00BSNM7G36.USD","LU1934455194.USD","LU1585245621.USD","LU0965509101.SGD","LU0882574055.USD","LU1934455863.HKD","BK4550","LU0109394709.USD"],"gpt_icon":0},{"id":"2621700089","title":"Gilead Nears up to $2Bn Deal for Autoimmune Biotech Ouro Medicines - FT","url":"https://stock-news.laohu8.com/highlight/detail?id=2621700089","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621700089?lang=en_us&edition=fundamental","pubTime":"2026-03-24 00:34","pubTimestamp":1774283675,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nFWN40B108:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BZ1G4Q59.USD","LU1057294990.SGD","LU1778281490.HKD","LU1066053197.SGD","LU1585245621.USD","SG9999015945.SGD","SG9999015978.USD","LU0122379950.USD","LU1674673428.USD","LU1066051498.USD","LU0320765992.SGD","IE00B7SZLL34.SGD","LU0114720955.EUR","LU0289739699.SGD","LU2324357040.USD","LU0058720904.USD","LU0109394709.USD","LU0234570918.USD","LU1023059063.AUD","BK4588","LU2112291526.USD","LU0965508806.USD","IE00B19Z3581.USD","LU1934455194.USD","IE00BSNM7G36.USD","IE00B19Z3B42.SGD","LU2468319806.SGD","IE00B3T34201.USD","LU1839511570.USD","LU0823416689.USD","BK4550","BK4532","LU0882574055.USD","LU1571399168.USD","GILD","LU1430594728.SGD","LU1934455277.USD","BK4566","LU2087621335.USD","BK4585","BK4568","LU1037948897.HKD","IE0002270589.USD","BK4578","LU0965509010.AUD","LU0965509101.SGD","BK4583","BK4139","LU1934455863.HKD","LU1037948541.HKD"],"gpt_icon":0},{"id":"2621700014","title":"Gilead Will Pay Privately Held Ouro’s Investors Roughly $1.5Bn Upfront in Cash and at Least Extra $500Mn IF Certain Clinical Trial Milestones Are Hit - FT","url":"https://stock-news.laohu8.com/highlight/detail?id=2621700014","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621700014?lang=en_us&edition=fundamental","pubTime":"2026-03-24 00:34","pubTimestamp":1774283675,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nFWN40B108:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1023059063.AUD","LU1057294990.SGD","LU1066053197.SGD","LU1061106388.HKD","LU2468319806.SGD","IE00B3T34201.USD","LU0861579265.USD","LU1934455194.USD","IE00BSNM7G36.USD","LU1778281490.HKD","LU1674673691.USD","SG9999015986.USD","LU1571399168.USD","GILD","BK4566","LU1037948541.HKD","BK4585","IE00B19Z3581.USD","BK4578","LU0965509010.AUD","LU0965509101.SGD","BK4532","LU0965508806.USD","LU1674673428.USD","BK4583","BK4588","LU1585245621.USD","LU1934455863.HKD","LU0823416689.USD","LU1430594728.SGD","BK4550","LU0965509283.SGD","LU1839511570.USD","LU2087621335.USD","LU2324357040.USD","IE00BKVL7J92.USD","LU1934455277.USD","LU1066051498.USD","IE0002270589.USD","SG9999015978.USD","LU0889565916.HKD","LU0289739699.SGD","LU2112291526.USD","LU2089984988.USD","LU0234570918.USD","LU0109394709.USD","BK4568","IE00BZ1G4Q59.USD","LU0882574055.USD","SG9999015952.SGD"],"gpt_icon":0},{"id":"2621700011","title":"Talks Between Gilead and Ouro Medicines Are at an Advanced Stage and a Deal Could Be Announced in the Coming Days - FT","url":"https://stock-news.laohu8.com/highlight/detail?id=2621700011","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621700011?lang=en_us&edition=fundamental","pubTime":"2026-03-24 00:34","pubTimestamp":1774283675,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nFWN40B108:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2087621335.USD","LU0114720955.EUR","LU0109394709.USD","BK4532","LU1037948541.HKD","LU1585245621.USD","LU1934455863.HKD","IE00B19Z3B42.SGD","LU2112291526.USD","SG9999015978.USD","IE00B19Z3581.USD","LU1066051498.USD","BK4588","IE00BSNM7G36.USD","LU0965508806.USD","LU2324357040.USD","LU0289739699.SGD","LU0965509101.SGD","LU0234570918.USD","GILD","LU1778281490.HKD","LU0965509010.AUD","IE00BZ1G4Q59.USD","LU0823416689.USD","LU1430594728.SGD","LU0320765992.SGD","LU1037948897.HKD","BK4578","LU0122379950.USD","BK4566","LU1571399168.USD","LU1023059063.AUD","BK4585","IE00B7SZLL34.SGD","LU1057294990.SGD","BK4550","LU1839511570.USD","LU0882574055.USD","SG9999015945.SGD","LU1066053197.SGD","LU2468319806.SGD","LU1674673428.USD","LU0058720904.USD","IE00B3T34201.USD","BK4583","LU1934455194.USD","BK4568","LU1934455277.USD","IE0002270589.USD","BK4139"],"gpt_icon":0},{"id":"2621047987","title":"Barclays Adjusts Viatris Price Target to $17 From $15, Maintains Overweight Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2621047987","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621047987?lang=en_us&edition=fundamental","pubTime":"2026-03-23 22:37","pubTimestamp":1774276627,"startTime":"0","endTime":"0","summary":"Price: 13.30, Change: +0.10, Percent Change: +0.76","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2087621335.USD","BK4585","VTRS","BK4588","LU1839511570.USD","BK4583","BK4007"],"gpt_icon":0},{"id":"2621674706","title":"Shareholders Sue Inovio Pharmaceuticals Over DNA Technology Claims","url":"https://stock-news.laohu8.com/highlight/detail?id=2621674706","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621674706?lang=en_us&edition=fundamental","pubTime":"2026-03-23 20:41","pubTimestamp":1774269717,"startTime":"0","endTime":"0","summary":"A class action lawsuit was filed against Inovio Pharmaceuticals ($INO) on February 6, 2026. Plaintiffs – shareholders – in the federal securities c...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/shareholders-sue-inovio-pharmaceuticals-over-dna-technology-claims?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/shareholders-sue-inovio-pharmaceuticals-over-dna-technology-claims?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4121","DNA","INO","BK4568","BK4109","BK4583","BK4139"],"gpt_icon":0},{"id":"2621770766","title":"Xilio Therapeutics Q4 license revenue rose 100% to USD 14 million, net income was USD 10 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2621770766","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621770766?lang=en_us&edition=fundamental","pubTime":"2026-03-23 19:31","pubTimestamp":1774265500,"startTime":"0","endTime":"0","summary":"Xilio published a press release with fourth-quarter and full-year 2025 financial results alongside pipeline and business updates.Q4 collaboration and license revenue rose more than sevenfold to USD 13.7 million, driven by revenue recognized under the AbbVie collaboration and higher revenue under the Gilead license tied to a development milestone.Q4 R&D expense more than doubled to USD 18.1 million, reflecting IND-enabling manufacturing and preclinical work for XTX501, higher efarindodekin alfa clinical development activity, and increased masked T cell engager program costs.Q4 net income was USD 10.4 million, compared with a net loss in the prior-year quarter.Cash and cash equivalents totaled USD 137.5 million at year-end, and Xilio said its cash runway is expected to extend through the end of 2027.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL77HrJ1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0912757837.SGD","LU0198837287.USD","IE00BN0W2T93.GBP","SG9999001440.SGD","BK4559","LU1674673428.USD","SG9999015952.SGD","LU0289739343.SGD","LU2210150020.SGD","IE00BBT3K403.USD","BK4566","LU2237443382.USD","IE00BFTCPJ56.SGD","BK4583","LU1778281490.HKD","IE00BGHQF631.EUR","ABBV","LU0320765992.SGD","LU0820561909.HKD","NDAQ","LU1057294990.SGD","LU0057025933.USD","LU2129689605.HKD","BK4139","IE0009355771.USD","LU0122379950.USD","IE00B64PRP62.GBP","LU1934455277.USD","LU2237443465.HKD","LU0211328371.USD","LU1162221912.USD","BK4578","LU1061106388.HKD","LU0320765646.SGD","LU2023251221.USD","IE00B3PB1722.GBP","IE00BLSP4452.SGD","LU0098860793.USD","GILD","LU1093756325.SGD","IE00BN0W2V16.EUR","XLO","LU0170899867.USD","BK4585","IE00B19Z3581.USD","IE00BKVL7J92.USD","LU0256863902.USD","LU2129689514.USD","LU1732800096.USD","LU2095319765.USD"],"gpt_icon":0},{"id":"2621779247","title":"Japan MHLW approves Viatris Effexor SR for adult generalized anxiety disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2621779247","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621779247?lang=en_us&edition=fundamental","pubTime":"2026-03-23 18:59","pubTimestamp":1774263583,"startTime":"0","endTime":"0","summary":"Japan’s Ministry of Health, Labour and Welfare approved Effexor SR  for treating generalized anxiety disorder in adults.The approval is based on a Phase 3 trial in Japan that met its primary endpoint at 8 weeks .Effexor was previously approved in Japan for major depressive disorder in adults.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viatris Inc. published the original content used to generate this news brief via PR Newswire  on March 23, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL8gvbLf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VTRS","BK4583","BK4588","BK4585","LU2087621335.USD","LU1839511570.USD","BK4007"],"gpt_icon":0},{"id":"2621777939","title":"Viatris Advances Innovative Portfolio With Approval of Effexor® in Japan for Adults With Generalized Anxiety Disorder (Gad)","url":"https://stock-news.laohu8.com/highlight/detail?id=2621777939","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621777939?lang=en_us&edition=fundamental","pubTime":"2026-03-23 18:59","pubTimestamp":1774263555,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nFWN40A04Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4583","BK4585","LU1839511570.USD","BK4588","VTRS","LU2087621335.USD"],"gpt_icon":0},{"id":"2621792717","title":"Assessing Viatris (VTRS) Valuation As Investor Event Outlines Long Term Plans Through 2030","url":"https://stock-news.laohu8.com/highlight/detail?id=2621792717","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621792717?lang=en_us&edition=fundamental","pubTime":"2026-03-22 07:08","pubTimestamp":1774134483,"startTime":"0","endTime":"0","summary":"Viatris (VTRS) has drawn fresh attention after announcing an Investor Event where leaders plan to lay out the company’s vision through 2030, including growth drivers, pipeline plans, portfolio choices, and capital return priorities.\nSee our latest analysis for Viatris.\nViatris shares currently trade at US$13.20, with a 30-day share price return of 17.76% decline, a 90-day share price return of 10.65%, and a 1-year total shareholder return of 50.99%.\nIf the Investor Event has you thinking...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vtrs/viatris/news/assessing-viatris-vtrs-valuation-as-investor-event-outlines","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vtrs/viatris/news/assessing-viatris-vtrs-valuation-as-investor-event-outlines","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1839511570.USD","BK4583","VTRS","BK4007","BK4588","LU2087621335.USD","BK4585"],"gpt_icon":0},{"id":"2621679220","title":"How Investors May Respond To Quest Diagnostics (DGX) Expanding Blood-Based Cancer Screening And Boardroom Expertise","url":"https://stock-news.laohu8.com/highlight/detail?id=2621679220","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621679220?lang=en_us&edition=fundamental","pubTime":"2026-03-22 07:07","pubTimestamp":1774134432,"startTime":"0","endTime":"0","summary":"In recent weeks, Guardant Health and Helio Genomics each announced agreements with Quest Diagnostics to distribute their blood-based colorectal and liver cancer screening tests through Quest’s nationwide network, while the Quest board also appointed experienced healthcare executive Timothy Wentworth as a new director.\nTogether, these moves deepen Quest’s role as an access point for innovative cancer detection while adding boardroom expertise in scaling complex healthcare platforms and...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6032000-choice1-main-header/1585186661957","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6032000-choice1-main-header/1585186661957"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-dgx/quest-diagnostics/news/how-investors-may-respond-to-quest-diagnostics-dgx-expanding","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-dgx/quest-diagnostics/news/how-investors-may-respond-to-quest-diagnostics-dgx-expanding","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1854103824.USD","BK4583","LU2506952170.USD","LU2506951958.HKD","BK4588","ISBC","DGX","LU0823417653.USD","LU2506951875.HKD","LU1854104046.USD","LU2506952097.USD","BK4196","BK4211","BK4567","LU0950375773.USD","LU0823417737.USD","BK4585"],"gpt_icon":0},{"id":"2621752587","title":"Inovio Pharmaceuticals Inc. Stock Underperforms Friday When Compared To Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2621752587","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621752587?lang=en_us&edition=fundamental","pubTime":"2026-03-21 05:26","pubTimestamp":1774041960,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Inovio Pharmaceuticals Inc.  slipped 4.24% to $1.58 Friday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ Composite Index  falling 2.01% to 21,647.61 and Dow Jones Industrial Average  falling 0.96% to 45,577.47.This was the stock's third consecutive day of losses.Inovio Pharmaceuticals Inc. closed 46.96% below its 52-week high of $2.98, which the company achieved on September 9th.The stock underperformed when compared to some of its competitors Friday, as Johnson & Johnson  fell 0.94% to $235.37, Statera Biopharma Inc.  remained unchanged, and Pfizer Inc.  fell 1.61% to $26.97.Trading volume  remained 8,994 below its 50-day average volume of 997,577.Data source: Dow Jones Market Data, FactSet. Data compiled March 20, 2026.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2505996681.GBP","SG9999013999.USD","LU1244550221.USD","LU2129689514.USD","LU0683600562.USD","IE0009355771.USD","IE00BLSP4239.USD","SG9999001440.SGD","INO","LU2602419157.SGD","LU1496350502.SGD","IE00BVYPNW00.USD","LU0170899867.USD","LU1244550494.USD","LU2471134952.CNY","IE0001KFT4U8.USD","LU0345770308.USD","LU0070217475.USD","BK4583","LU1506573853.SGD","BK4504","LU0787776722.HKD","IE00B1BXHZ80.USD","SG9999002224.SGD","LU0345769128.USD","IE00B2B36J28.USD","SGXZ57979304.SGD","LU0234570918.USD","LU0289739699.SGD","BK4599","IE00BVYPNV92.GBP","LU1929549753.HKD","LU0432979614.USD","LU2471134796.USD","LU1280957306.USD","LU0058720904.USD","IE00BSNM7G36.USD","LU0321505439.SGD","IE0034235303.USD","LU2089984988.USD","BK4585","LU2430703095.HKD","LU2505996509.AUD","IE00BDGV0183.EUR","LU0640476718.USD","LU2129689605.HKD","LU0889566641.SGD","LU2471134879.HKD","LU1023059063.AUD","LU0792757196.USD","IE00BJT1NW94.SGD","BK4533","LU1778281490.HKD","LU1196500208.SGD","LU1244550577.SGD","LU1066053197.SGD","LU1061106388.HKD","LU1674673691.USD","LU0689626769.HKD","IE00B3PB1722.GBP","LU0868494617.USD","SG9999003800.SGD","LU2112291526.USD","BK4588","LU1718418525.SGD","LU2471134523.USD","SG9999001176.SGD","IE00BJJMRZ35.SGD","BK4568","LU0234572021.USD","IE00B4R5TH58.HKD","LU0795875169.SGD","LU1162221912.USD","IE00BN8TJ469.HKD","LU0306806265.USD","IE00BZ1G4Q59.USD","LU1894683264.USD","LU0203347892.USD","LU1066051811.HKD","LU0203345920.USD","LU1674673428.USD","LU0114720955.EUR","IE00B42XCP33.USD","LU1894683348.USD","LU1032466523.USD","LU1267930813.SGD","LU0320765646.SGD","IE0002270589.USD","LU0122379950.USD","LU2468319806.SGD","LU0345769631.USD","LU0985320562.USD","LU0795875086.SGD","LU2592432038.USD","IE000M9KFDE8.USD","LU1935042991.SGD","IE00BKVL7J92.USD","LU0225284248.USD","LU0098860793.USD","LU2347655156.SGD","BK4550","SG9999002232.USD","SG9999001176.USD","LU1221951046.USD","IE00BGHQF631.EUR","LU1066051498.USD","LU1057294990.SGD","LU2430703251.USD","BK4559","LU1585245621.USD","IE00B3T34201.USD","BK4581","BK4532","LU1221951129.SGD","LU1430594728.SGD","LU1983299246.USD","LU0225771236.USD","BK4139","IE00B19Z3B42.SGD","IE00BLSP4452.SGD","LU0124676726.USD","LU0306807586.USD","IE0002141913.USD","LU1066051225.USD","LU1732800096.USD","LU1883839398.USD","BK4592","LU0456855351.SGD","LU2129689431.USD","SG9999011175.SGD","LU2750360641.GBP","LU1261432733.SGD","IE00BFXG1179.USD","BK4007","LU0985481810.HKD","IE00BBT3K403.USD","IE00B7SZLL34.SGD","LU1732799900.SGD","LU1059921491.USD","LU0321505868.SGD","LU2430703178.SGD","LU0912757837.SGD","IE00BFTCPJ56.SGD","LU1032955483.USD","LU0882574055.USD","LU2750360997.AUD","LU1914381329.SGD","LU0466842654.USD","LU2133065610.SGD","LU1074936037.SGD","LU0345770993.USD","BK4534","IE00B19Z3581.USD"],"gpt_icon":0},{"id":"2621754712","title":"Tonix Pharmaceuticals Holding Corp. Announces Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2621754712","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621754712?lang=en_us&edition=fundamental","pubTime":"2026-03-21 05:14","pubTimestamp":1774041245,"startTime":"0","endTime":"0","summary":"Tonix will hold its annual shareholder meeting online on May 7, 2026.Shareholders are scheduled to vote on the election of nine director nominees.The agenda also includes authorizing the board to implement one or more reverse stock splits with an aggregate ratio between 1-for-2 and 1-for-250 within two years.Additional business includes approval of the Tonix 2026 Stock Incentive Plan.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tonix Pharmaceuticals Holding Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 20, 2026, and is solely responsible for the information contained ther","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nNDLFZdvB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TNXP","BK4583","BK4139"],"gpt_icon":0},{"id":"2621754699","title":"Emergent BioSolutions Inc. Announces Annual Meeting of Stockholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2621754699","media":"Reuters","labels":["conferences","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621754699?lang=en_us&edition=fundamental","pubTime":"2026-03-21 04:52","pubTimestamp":1774039974,"startTime":"0","endTime":"0","summary":"Emergent BioSolutions will hold its annual meeting virtually on April 29, 2026.Shareholders will vote to elect Sujata Dayal, John Fowler, Jr., Zsolt Harsanyi, and Joseph Papa as Class II directors for terms expiring at the 2029 annual meeting.Investors will also cast an advisory vote on approval of 2025 compensation for the company’s named executive officers.Another proposal seeks approval of an amendment to the stock incentive plan to increase the number of shares available for awards by 5.0 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Emergent BioSolutions Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nNDL4RHFbk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EBS","BK4583"],"gpt_icon":0},{"id":"2621747751","title":"Gilead Sciences Inc. Stock Underperforms Friday When Compared To Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2621747751","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621747751?lang=en_us&edition=fundamental","pubTime":"2026-03-21 04:35","pubTimestamp":1774038900,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Gilead Sciences Inc.  shed 2.76% to $137.21 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index  falling 1.51% to 6,506.48 and Dow Jones Industrial Average  falling 0.96% to 45,577.47.This was the stock's fourth consecutive day of losses.Gilead Sciences Inc. closed 12.77% short of its 52-week high of $157.29, which the company achieved on February 11th.The stock underperformed when compared to some of its competitors Friday, as Johnson & Johnson  fell 0.94% to $235.37, Pfizer Inc.  fell 1.61% to $26.97, and Abbott Laboratories  fell 1.61% to $105.46.Trading volume  eclipsed its 50-day average volume of 7.4 M.Data source: Dow Jones Market Data, FactSet. Data compiled March 20, 2026.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2129689431.USD","IE0002270589.USD","IE00BVYPNV92.GBP","SG9999015986.USD","LU0321505868.SGD","LU1721429402.USD","LU1732799900.SGD","LU0225284248.USD","LU0689626769.HKD","SG9999015952.SGD","SGXZ23171101.USD","BK4568","SG9999001176.USD","IE00BSNM7G36.USD","LU1674673691.USD","LU0792757196.USD","LU2129689605.HKD","LU0912757837.SGD","SGXZ57979304.SGD","BK4139","IE00B19Z3581.USD","LU0456855351.SGD","LU0965509101.SGD","LU2129689514.USD","SG9999001440.SGD","LU1894683348.USD","LU0985320562.USD","SG9999002232.USD","LU1934455863.HKD","LU2237957902.USD","LU0985481810.HKD","LU1261432733.SGD","LU1894683264.USD","IE00BVYPNW00.USD","LU0889565916.HKD","LU0122379950.USD","BK4588","LU0889566641.SGD","LU0234572021.USD","BK4583","IE00B7SZLL34.SGD","BK4592","LU2471134879.HKD","LU2211815571.USD","IE00B3PB1722.GBP","LU0114720955.EUR","LU0225771236.USD","LU0795875086.SGD","BK4534","LU1074936037.SGD","LU1989763690.USD","LU2471134952.CNY","LU2602419157.SGD","IE00BBT3K403.USD","LU0234570918.USD","LU0466842654.USD","LU1066053197.SGD","LU0266013472.USD","IE00B3T34201.USD","IE00B4R5TH58.HKD","LU1280957306.USD","LU1032955483.USD","LU0124676726.USD","LU0823416689.USD","SG9999013999.USD","LU2430703095.HKD","LU2324357040.USD","LU1839511570.USD","IE00BDGV0183.EUR","LU0965508806.USD","LU1934455194.USD","BK4566","IE0034235303.USD","LU0320765646.SGD","LU1732800096.USD","IE00B1BXHZ80.USD","LU1883839398.USD","BK4599","IE00BLSP4239.USD","LU0965509010.AUD","LU0345770308.USD","BK4585","LU1571399168.USD","LU0098860793.USD","LU0345769631.USD","LU1244550577.SGD","LU1691799644.USD","SG9999004303.SGD","LU0795875169.SGD","SG9999011175.SGD","SG9999001176.SGD","SG9999015945.SGD","LU1267930813.SGD","BK4007","LU1935042991.SGD","LU0306806265.USD","LU1585245621.USD","LU0345770993.USD","LU1496350502.SGD","LU1066051225.USD","LU2505996509.AUD","BK4578","LU2750360997.AUD","IE00BZ1G4Q59.USD","LU2112291526.USD","LU2471134523.USD","IE00BLSP4452.SGD","IE000M9KFDE8.USD","LU1430594728.SGD","LU1914381329.SGD","IE00B42XCP33.USD","LU0203347892.USD","LU0070217475.USD","LU2468319806.SGD","LU0861579265.USD","LU1718418525.SGD","LU1989763427.SGD","BK4533","IE0001KFT4U8.USD","IE0009355771.USD","LU1196500208.SGD","IE00BN8TJ469.HKD","LU2505996681.GBP","IE00B19Z3B42.SGD","LU1162221912.USD","LU1929549753.HKD","LU1059921491.USD","LU2089984988.USD","LU0289739699.SGD","BK4504","LU0109394709.USD","LU1037948541.HKD","LU1066051811.HKD","LU1244550221.USD","LU1778281490.HKD","LU1061106388.HKD","LU0868494617.USD","BK4559","LU0683600562.USD","LU1983299246.USD","LU2430703251.USD","IE00BFTCPJ56.SGD","LU1721429741.USD","LU0306807586.USD","LU0345769128.USD","IE00BJT1NW94.SGD","LU2133065610.SGD","BK4581","IE0002141913.USD","LU1037948897.HKD","IE00B2B36J28.USD","SGXZ41872573.SGD","LU1066051498.USD","GILD","BK4082","LU2237957811.SGD","LU1023059063.AUD","LU1221951046.USD","LU1934455277.USD","LU1506573853.SGD","IE00BKVL7J92.USD","LU1057294990.SGD","IE00BFXG1179.USD","LU0321505439.SGD","SG9999002224.SGD","LU1221951129.SGD","IE00BGHQF631.EUR","LU0432979614.USD","LU0203345920.USD","LU0640476718.USD","LU0787776722.HKD","LU0882574055.USD","BK4550","LU1032466523.USD","LU2087621335.USD","BK4532","LU0320765992.SGD","LU2430703178.SGD","LU0965509283.SGD","LU0170899867.USD","LU1244550494.USD","IE00BJJMRZ35.SGD","LU2471134796.USD","LU2750360641.GBP","LU1674673428.USD","LU0058720904.USD","LU2592432038.USD","SG9999003800.SGD","LU2347655156.SGD","SG9999015978.USD"],"gpt_icon":0},{"id":"2621751281","title":"E-Home Household Service set for Nasdaq delisting hearing on April 16, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2621751281","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621751281?lang=en_us&edition=fundamental","pubTime":"2026-03-21 04:30","pubTimestamp":1774038643,"startTime":"0","endTime":"0","summary":"On March 16, 2026, E-Home said it received a Nasdaq notice stating its shares failed to maintain a $1.00 minimum bid price for 30 consecutive business days.Nasdaq determined to delist the company’s securities from the Nasdaq Capital Market, with trading suspension previously set for March 25, 2026.The company requested a hearing on March 17, 2026, which stayed the suspension and delisting pending the hearing process.A hearing before a Nasdaq panel is scheduled for April 16, 2026, and E-Home said it plans to submit a compliance plan.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. E-Home Household Service Holdings Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nNDL4kJQg7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","EJH","BK4539","BK4192"],"gpt_icon":0},{"id":"2621391751","title":"Gilead Sciences Inc. Announces Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2621391751","media":"Reuters","labels":["shareholding","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621391751?lang=en_us&edition=fundamental","pubTime":"2026-03-21 04:03","pubTimestamp":1774037003,"startTime":"0","endTime":"0","summary":"Gilead will hold its annual meeting on April 30, 2026, via webcast.Shareholders will vote on electing nine director nominees to serve for the next year.Items up for approval include ratifying Ernst and Young as independent auditor and an advisory vote on named executive officer compensation.Shareholders will also vote on approving an amended and restated 2022 equity incentive plan.Three shareholder proposals will be voted on, covering an independent board chair policy, a report on extended patent exclusivities and patient access, and a report on risks of ESG and DEI executive compensation metrics.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief via EDGA","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nNDL6SPJn6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU1430594728.SGD","SG9999015986.USD","LU1674673691.USD","IE00B3T34201.USD","GILD","BK4585","IE00B19Z3B42.SGD","LU0965508806.USD","LU1674673428.USD","LU0234570918.USD","LU1066053197.SGD","LU0965509101.SGD","BK4532","IE00B7SZLL34.SGD","LU1057294990.SGD","LU1571399168.USD","LU0823416689.USD","LU0965509010.AUD","LU0122379950.USD","LU0882574055.USD","LU0109394709.USD","LU1066051498.USD","IE00BZ1G4Q59.USD","LU0965509283.SGD","LU1061106388.HKD","LU1585245621.USD","LU2089984988.USD","LU0289739699.SGD","BK4566","SG9999015952.SGD","BK4568","IE00BSNM7G36.USD","LU2112291526.USD","IE00BKVL7J92.USD","SG9999015945.SGD","IE00B19Z3581.USD","LU1934455863.HKD","LU0114720955.EUR","BK4550","LU0058720904.USD","LU2324357040.USD","LU1839511570.USD","LU0861579265.USD","BK4578","LU0320765992.SGD","SG9999015978.USD","LU1037948541.HKD","BK4583","LU1023059063.AUD"],"gpt_icon":0},{"id":"2621758752","title":"Gilead Ends Obeldesivir Filovirus Prophylaxis Trial: What It Means for GILD Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2621758752","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621758752?lang=en_us&edition=fundamental","pubTime":"2026-03-21 00:30","pubTimestamp":1774024229,"startTime":"0","endTime":"0","summary":"Gilead Sciences ($GILD) announced an update on their ongoing clinical study. The Phase 2 study titled “A Phase 2, Single-Arm Study of Obeldesivir f...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gilead-ends-obeldesivir-filovirus-prophylaxis-trial-what-it-means-for-gild-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gilead-ends-obeldesivir-filovirus-prophylaxis-trial-what-it-means-for-gild-investors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LU2089984988.USD","SG9999015978.USD","LU1037948541.HKD","IE00B19Z3B42.SGD","LU0965508806.USD","GILD","LU0114720955.EUR","LU0122379950.USD","LU1934455194.USD","LU0058720904.USD","LU1061106388.HKD","BK4139","BK4550","BK4588","LU1037948897.HKD","LU2112291526.USD","IE00B3T34201.USD","IE00BKVL7J92.USD","LU2468319806.SGD","BK4532","SG9999015986.USD","SG9999015952.SGD","LU1934455277.USD","LU0882574055.USD","LU1066051498.USD","LU1066053197.SGD","BK4566","LU1057294990.SGD","LU1934455863.HKD","LU2324357040.USD","IE00BSNM7G36.USD","BK4211","BK4568","LU1585245621.USD","LU0109394709.USD","IE00B7SZLL34.SGD","BK4583","LU0823416689.USD","IE00BZ1G4Q59.USD","LU0965509010.AUD","LU1839511570.USD","ISBC","IE0002270589.USD","LU0861579265.USD","LU1430594728.SGD","LU1778281490.HKD","BK4578","LU2087621335.USD","LU0965509101.SGD"],"gpt_icon":0},{"id":"2620738732","title":"Virax Biolabs Group Ltd. COO and Director Nigel William McCracken files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620738732","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620738732?lang=en_us&edition=fundamental","pubTime":"2026-03-20 22:43","pubTimestamp":1774017832,"startTime":"0","endTime":"0","summary":"Virax Biolabs reported that director and Chief Operating Officer Nigel McCracken holds stock options for 120,000 ordinary shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Virax Biolabs Group Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 20, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nNDLqQ7Cz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRAX","BK4583","BK4175"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":89,"code":"91000000","status":"200"}]}}